Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Merck
Julphar
Cantor Fitzgerald
Covington
Accenture
UBS
Moodys

Generated: December 16, 2018

DrugPatentWatch Database Preview

ALIMTA Drug Profile

« Back to Dashboard

When do Alimta patents expire, and when can generic versions of Alimta launch?

Alimta is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug and four Paragraph IV challenges.

This drug has seventeen patent family members in eleven countries.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pemetrexed disodium profile page.

Drug patent expirations by year for ALIMTA
Generic Entry Opportunity Date for ALIMTA
Generic Entry Date for ALIMTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ALIMTA
Synonyms for ALIMTA
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-{[4-(2-{2-amino-4-oxo-1H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
(S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
(S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic
(S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
(S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
04Q9AIZ7NO
137281-23-3
150399-23-8
1juj
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
281P233
2PKU919BA9
357166-30-4
41413-EP2270012A1
41413-EP2270013A1
41413-EP2305681A1
41413-EP2311838A1
41421-EP2270012A1
41421-EP2270013A1
41421-EP2305681A1
41421-EP2311838A1
4DW
89077-EP2270012A1
89077-EP2270013A1
89077-EP2305681A1
AB01273937-01
AC-1326
AC-1701
AC1L9JT6
AC1OCF51
AJ-26845
AK-72902
AK325951
AKOS015896253
AKOS025149477
AKOS025392176
Alimta (TN) (Lilly)
BC215781
BDBM18796
BDBM50027656
BG0632
BR-72902
C20H19N5Na2O6
C20H19N5O6.2Na.7H2O
C20H21N5O6
CAS-150399-23-8
CCG-213071
CCG-221272
CHEBI:63616
CHEBI:63722
CHEMBL225072
CHEMBL2360464
CP0067
CP0119
CS-1297
CS-1298
CS-W004541
CTK8E6673
D03828
D07472
DB-024764
DB00642
disodium (2S)-2-({4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}amino)pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
disodium N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamate
DSSTox_CID_26660
DSSTox_GSID_46660
DSSTox_RID_81803
DTXSID2048329
DTXSID8046660
EX-A836
FT-0659328
H518
HMS3264H07
HSDB 7316
HY-10820
HY-10820A
I06-2128
J-502393
KB-78231
KB-79792
KS-00000GW0
KS-00000XJK
KS-5001
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-
L-Glutamic acid,3-d]pyrimidin-5-yl]ethyl]benzoyl]-
LY-2315
LY-231514
LY231514
LY231514 disodium
LYA
MolPort-003-849-796
MolPort-016-638-470
MolPort-020-179-988
N-(4-[2-(2-amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-Glutamic Acid
N-(4-[2-(2-Amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-Glutamic Acid Disodium Salt
N-(4-[2-(2-Amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5yl)ethyl]benzoyl)-L-Glutamic Acid Disodium Salt
N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimi-din-5-yl)ethyl]benzoyl]l-glutamic acid
N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2.3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt
N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid
N-[4-[2-[2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]glutamic acid
N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid
N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid
N-[4[2-(-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamate sodium salt
N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid
N-{4-[2-(2-Amino-4-Oxo-4,7-Dihydro-3h-Pyrrolo[2,3-D]pyrimidin-5-Yl)ethyl]benzoyl}-L-Glutamic Acid
NCGC00167486-01
NCGC00167517-01
NCGC00242485-01
NSC-698037
NSC698037
NYDXNILOWQXUOF-GXKRWWSZSA-L
P2288
Pemetrexed
Pemetrexed (disodium)
Pemetrexed (INN)
Pemetrexed (TN)
Pemetrexed acid
pemetrexed diacid monohydrate
Pemetrexed disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
PEMETREXED DISODIUM 5/2 hydrate
Pemetrexed disodium salt
Pemetrexed disodium, anhydrous
Pemetrexed Na
Pemetrexed Sodium
Pemetrexed sodium hydrate
Pemetrexeddisodium
Premetred disodium
Premetrexed [Common mis-spelling]
Rolazar
RP17940
RP17947
S-4927
s1135
SC-25136
SCHEMBL18348
SCHEMBL7968
sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
Tifolar
Tox21_112487
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
X5918
ZINC1540998

US Patents and Regulatory Information for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 ➤ Sign Up ➤ Sign Up
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 ➤ Sign Up ➤ Sign Up
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 ➤ Sign Up ➤ Sign Up
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ALIMTA
Drugname Dosage Strength RLD Date
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe ➤ Sign Up
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe ➤ Sign Up
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe ➤ Sign Up
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for ALIMTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2005 Austria ➤ Sign Up PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920
C/GB05/011 United Kingdom ➤ Sign Up PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Merck
Julphar
Cantor Fitzgerald
Covington
Accenture
UBS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.